Both acute and prolonged administration of EPO reduce cerebral and systemic vascular conductance in humans

Administration of erythropoietin (EPO) has been linked to cerebrovascular events. EPO reduces vascular conductance, possibly because of the increase in hematocrit. Whether EPO in itself affects the vasculature remains unknown; here it was evaluated in healthy males by determining systemic and cerebr...

Full description

Saved in:
Bibliographic Details
Published in:The FASEB journal 2012-03, Vol.26 (3), p.1343-1348
Main Authors: Rasmussen, Peter, Kim, Yu‐Sok, Krogh‐Madsen, Rikke, Lundby, Carsten, Olsen, Niels V., Secher, Niels H., Lieshout, Johannes J.
Format: Article
Language:English
Subjects:
Adult
Blood Flow Velocity - drug effects
Blood Pressure - drug effects
Cerebrovascular Circulation - drug effects
Cross-Over Studies
Double-Blind Method
Erythropoietin - administration & dosage
Erythropoietin - pharmacology
Exercise
Hematocrit
Homeostasis - drug effects
Humans
hypoxia
Injections, Intravenous
Injections, Subcutaneous
Male
neuroprotective agents
Oxygen - metabolism
Oxygen Consumption - drug effects
Time Factors
Vasoconstriction - drug effects
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Administration of erythropoietin (EPO) has been linked to cerebrovascular events. EPO reduces vascular conductance, possibly because of the increase in hematocrit. Whether EPO in itself affects the vasculature remains unknown; here it was evaluated in healthy males by determining systemic and cerebrovascular variables following acute (30,000 IU/d for 3 d; n=8) and chronic (5000 IU/week for 13 wk; n=8) administration of EPO, while the responsiveness of the vasculature was challenged during cycling exercise, with and without hypoxia. Prolonged administration of EPO increased hematocrit from 42.5 ± 3.7 to 47.6 ± 4.1% (P
ISSN:0892-6638
1530-6860
DOI:10.1096/fj.11-193508